Jonathan Tomaszewski (@dr_jonathant) header
Jonathan Tomaszewski (@dr_jonathant) profile picture

Radiation Oncologist, Ballarat Austin Radiation Oncology Centre • Views my own #radonc 🇦🇺

Victoria, Australia
Joined July 2014
Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)Photo by Jonathan Tomaszewski (@dr_jonathant)
V interesting article, suspect a lot of practice variation here #radonc @TylerSbrt @alison_tree @jryckman3
New in #practicalRO: Peri-rectal Nodal Clinical Target Volume (CTV) Delineation in Patients with Prostate Cancer. #radonc tinyurl.com/probjdavis
1
671
Might this now be possible with the POSEIDON dataset @AmarUKishan? Calculator showing 10yr MFS with RT (+/- HT) based on pre RT PSA & path features would be v useful, pending widely avail biomarker #radonc #pcsm
Would be really helpful to be able to generate individualised estimates of MFS/PCSS/OS for salvage RT alone (beyond the subgroup data from Supp Table 4). Any plans for a nomogram/calculator, or suggestions re how to go about this? #radonc #pcsm
1
556
Would be really helpful to be able to generate individualised estimates of MFS/PCSS/OS for salvage RT alone (beyond the subgroup data from Supp Table 4). Any plans for a nomogram/calculator, or suggestions re how to go about this? #radonc #pcsm
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/ar… This systematic review and meta-analysis by the DADSPORT Collaboration evaluated the impact of hormone therapy (HT) added to postoperative radiotherapy (RT) in nonmetastatic #ProstateCancer across five randomized controlled trials involving 4,411 participants. While HT did not significantly improve overall survival (OS) in the general population, it did show meaningful benefits in metastasis-free survival (MFS) and prostate cancer–specific survival (PCSS), each with a 4% absolute improvement at 8 years. Notably, OS benefits may be limited to patients with higher pre-RT PSA levels or CAPRA-S scores. These findings support the use of adjuvant HT to improve cancer outcomes, particularly in higher-risk patients. @DrSpratticus @AmarUKishan @drjefstathiou @PCaParker @_APollack @PaulSargos @felixfengmd @OncoAlert @Silke_Gillessen @AOmlin @nataliagandur @bavilima
1
2
1
8
2,654
Curious to hear from #radonc re whether they contour & limit lumbosacral plexus when boosting involved pelvic nodes in #prostatecancer? (e.g PEACE V used 65Gy/25# which is 74.75Gy EQD2 for a/b=2) 🤔 @alison_tree @PBlanchardMD @piet_ost @dr_alimuhammad @TylerSbrt
10
1
13
2,673
OCUM trial n=~1100 but majority not informative re RT omission. Key group n=257, stage II/III <12cm from verge treated with upfront surg (MRF>1mm, no T4 or low T3, vast majority N≤1 & 6-12cm from verge) ➡️ 5yr LR 3.8%. No info re T3 substage/EMVI ascopubs.org/doi/full/10.120… #radonc
1
6
3
18
10,318
Jonathan Tomaszewski retweeted
🚨🚨🚨 PROSPECT Trial has landed! Congratulations to all investigators, @ALLIANCE_org, for this important trial! This study is important, will shape, and SHOULD alter practice for OPERATIVELY managed patients with favorable risk LA- rectal cancer. nejm.org/doi/full/10.1056/NE…
4
76
16
151
107,778
Jonathan Tomaszewski retweeted
New ESTRO ACROP GUIDELINE on Prostate Bed Delineation for Postoperative Radiotherapy in Prostate Cancer! Great work!! ⁦@a_dalpra⁩ ⁦@agomeziturriaga⁩ ⁦@AlbertoBossial⁩ sciencedirect.com/science/ar…
1
62
1
121
12,555
How will this stack up against the Spratt criteria? 🧐 https://teapawt.org/t.co/KmI8qcHy6U #radonc #pcsm
GETUG-AFU 22 efficacy results presented in Milan. Great discussion with chairs. To be published soon... 🇮🇹🇫🇷
1
1
1,221
Jonathan Tomaszewski retweeted
My arguments presented this morning #EAU23 for #radiotherapy + ADT/ARPA in patients with localized high risk PSMA-N1 BRCA mutated #prostatecancer. Major thanks to all who provided input! Two parts: 1. RT/ADT/ARPA is SOC
Hey #prostatecancer tweeps, I need your help to support the use of #radiotherapy at a debate at next EAU meeting... topic: 49 yo pt with germline BRCA2 mutation cT3a PSA 45 ISUP2 N0 on CI but N1 on PSMA M0 arguments + references much appreciated...
2
21
55
7,593
Full time consultant position available - join our team in Ballarat! 🇦🇺👇 https://teapawt.org/t.co/ud5zl18yBp
280
Would interpret with great caution. Small numbers, retrospective & conflicts with randomised data incl RAPIDO showing equivalent QoL/LARS/late GI tox (https://teapawt.org/t.co/SihQjTUheJ) #radonc #rectalcancer
Read our work on bowel functional outcomes after short or long-course radiation for rectal cancers in @DCRjournal from @TataMemorial Greater incidence of any low anterior resection syndrome after SCRT, similar incontinence @DCREdInChief @TechColoproctol @ColorectalDis
1
1
3
1,032
Fantastic overview of recent & historical loc adv #rectalcancer trials & framework for TNT decision-making #radonc #gicsm @tarik_sammour
Hey Friends! Let’s discuss management of locally advanced rectal cancer! #RadOnc #GIOnc Check out the results of this poll! teapawt.org/KrishanJethwa/status/1… Let’s dive in to review! 🧵 🧵 1/
1
2
5
1,393
Respected voices in #skincancer #radonc offering their perspective and urging caution re wide field RT/VMAT for “skin field cancerisation” https://teapawt.org/t.co/9yOGBF3Vno
3
6
Wonder if #dermtwitter has any thoughts to share on this thread? 👇 @MDJenniferChoi
Think RT likely to be safe in pts with albinism but will tag others for their thoughts @Sushilberiwal @CatharineWest3 @xrtGenomics @carmenbergom @HenningWillers #radonc
1
Think RT likely to be safe in pts with albinism but will tag others for their thoughts @Sushilberiwal @CatharineWest3 @xrtGenomics @carmenbergom @HenningWillers #radonc
hello #radonc and #medtwitter community! may I ask you a question please! Do you have any experience in treating patients having albinism for prostate #pcsm cancer with radiotherapy ? Do you think that there is any major risk of toxicity or second cancers?Thank you for answering!
1
1
3
A recurring discussion - such is the nature of Twitter (https://teapawt.org/t.co/wDC9kaLblV). Inevitably #radonc will come across as defensive, so pleasing to see perspective offered by Urologists in this thread @uroegg @chrisfilson_uro @ChapinMD
This Post is from an account that no longer exists. Learn more
3
This Post is from an account that no longer exists. Learn more
1
"We, therefore, conclude that higher CV risk should be managed optimally in the CV sense but this finding should not be an indication for the preferential use of LHRH an- tagonists in patients with prostate cancer." #pcsm #prostatecancer @JCO_ASCO ascopubs.org/doi/full/10.120…
4